Translational Medicine in Neurological Disorders: A Genomic Perspective

Author(s): Giulia Gentile , Sebastiano Cavallaro* .

Journal Name: Current Genomics

Volume 20 , Issue 3 , 2019

Become EABM
Become Reviewer

[1]
Cohrs, R.J.; Martin, T.; Ghahramani, P.; Bidaut, L.; Higgins, P.J.; Shahzad, A. Translational medicine definition by the european society for translational medicine. Eur. J. Mol. Clin. Med., 2014, 2(3), 86-88.
[2]
World Health Organization; Neurological Disorders: Public Health Challenges., 2006.Available from. https://www.who.int/mental_ health/neurology/neurodiso/en/
[3]
Levi-Montalcini, R.; Calissano, P. The scientific challenge of the 21st century: from a reductionist to a holistic approach via systems biology. BMC Neurosci., 2006, 7(S1), S1.
[4]
Parikshak, N.N.; Gandal, M.J.; Geschwind, D.H. Systems biology and gene networks in neurodevelopmental and neurodegenerative disorders. Nat. Rev. Genet., 2015, 16(8), 441-458.
[5]
Neurological diseases remain neglected and ignored. Lancet, 2012, 379(9813), 287.Available from.
[http://dx.doi.org/10.1016/S0140-6736(12)60123-8]
[6]
Sweeney, P.; Park, H.; Baumann, M.; Dunlop, J.; Frydman, J.; Kopito, R.; McCampbell, A.; Leblanc, G.; Venkateswaran, A.; Nurmi, A. Protein misfolding in neurodegenerative diseases: implications and strategies. Transl. Neurodegener., 2017, 6(1), 6.
[7]
Vita, G.; Vita, G.L.; Stancanelli, C.; Gentile, L.; Russo, M.; Mazzeo, A. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies. Neurol. Sci., 2019, 40(4), 661-669.
[8]
Vita, G.; Vita, G.L.; Musumeci, O.; Rodolico, C.; Messina, S. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle. Neurol. Sci., 2019, 40(4), 671-681.
[9]
Wang, D.; Liu, S.; Warrell, J.; Won, H.; Shi, X.; Navarro, F.C.P.; Clarke, D.; Gu, M.; Emani, P.; Yang, Y.T. Comprehensive functional genomic resource and integrative model for the human brain. Science., 2018, 362, (6420), eaat8464.
[10]
Morello, G.; Spampinato, A.G.; Conforti, F.L.; Cavallaro, S. Taxonomy meets neurology, the case of amyotrophic lateral sclerosis. Front. Neurosci., 2018, 12, 673.
[11]
Miller, D.T.; Adam, M.P.; Aradhya, S.; Biesecker, L.G.; Brothman, A.R.; Carter, N.P.; Church, D.M.; Crolla, J.A.; Eichler, E.E.; Epstein, C.J. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am. J. Hum. Genet., 2010, 86(5), 749-764.
[12]
Webb, B.D.; Scharf, R.J.; Spear, E.A.; Edelmann, L.J.; Stroustrup, A. Evaluation of the Affymetrix Cytoscan(®) Dx Assay for developmental delay. Expert Rev. Mol. Diagn., 2015, 15(2), 185-192.
[13]
La Cognata, V.; Morello, G.; Gentile, G.; Cavalcanti, F.; Cittadella, R.; Conforti, F.L.; De Marco, E.V.; Magariello, A.; Muglia, M.; Patitucci, A. NeuroArray : a customized ACGH for the analysis of copy number variations in neurological disorders. Curr. Genomics, 2018, 19(6), 431-443.
[14]
Matthijs, G.; Souche, E.; Alders, M.; Corveleyn, A.; Eck, S.; Feenstra, I.; Race, V.; Sistermans, E.; Sturm, M.; Weiss, M. Guidelines for diagnostic next-generation sequencing. Eur. J. Hum. Genet., 2016, 24(1), 2-5.
[15]
Klein, C.J.; Foroud, T.M. Neurology individualized medicine: when to use next-generation sequencing panels. Mayo Clin. Proc., 2017, 92(2), 292-305.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 3
Year: 2019
Page: [151 - 153]
Pages: 3
DOI: 10.2174/138920292003190704143857

Article Metrics

PDF: 15
HTML: 5